Pharmacogenomic Testing and Breast Cancer

Description: Dr. Hannah Linden, associate professor of medicine at the University of Washington, examines genomic heterogeneity, an emerging and important factor in determining tamoxifen benefit in breast cancer. Dr. Linden reviews recent laboratory and clinical trial evidence regarding tamoxifen metabolism and the impact of CYP2D6 pharacogenomic profiling.